Active Ingredient History
Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bone Diseases, Infectious (approved 2003)
Gonorrhea (approved 2003)
Intraabdominal Infections (approved 2003)
Meningitis (approved 2003)
Otitis Media (approved 2003)
Pelvic Inflammatory Disease (approved 2003)
Respiratory Tract Infections (approved 2003)
Sepsis (approved 2003)
Staphylococcal Skin Infections (approved 2003)
Urinary Tract Infections (approved 2003)
Abdominal Abscess (Phase 4)
Abscess (Phase 4)
Accidents (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 3)
Anesthesia and Analgesia (Phase 2)
Antibiotic Prophylaxis (Phase 3)
Appendicitis (Phase 4)
Arthritis, Infectious (Phase 4)
Bacterial Infections (Phase 4)
Bipolar Disorder (Phase 2)
Bone Diseases, Infectious (Phase 4)
Brain Diseases (Phase 2)
Cardiovascular Diseases (Phase 2)
Cartilage Diseases (Phase 2)
Central Nervous System Diseases (Phase 2)
Central Nervous System Infections (Phase 4)
Cerebral Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 2)
Child Nutrition Disorders (Phase 2/Phase 3)
Chlamydia (Phase 2)
Cholangitis (Phase 4)
Cholecystitis (Phase 4)
Colitis (Phase 2)
Colitis, Ulcerative (Phase 2)
Community-Acquired Infections (Phase 4)
COVID-19 (Phase 4)
Critical Illness (Phase 4)
Cross Infection (Phase 4)
Diabetes Mellitus (Phase 4)
Diarrhea (Phase 4)
Diverticulitis (Phase 4)
Drug Resistance, Bacterial (Phase 4)
Dysentery, Bacillary (Phase 2)
Endocarditis (Phase 4)
Endometritis (Phase 2)
Escherichia coli Infections (Phase 3)
Esophageal and Gastric Varices (Phase 4)
Fractures, Open (Phase 4)
Gastrointestinal Hemorrhage (Phase 4)
General Surgery (Phase 4)
Gonorrhea (Phase 4)
Healthcare-Associated Pneumonia (Phase 3)
Healthy Volunteers (Phase 2/Phase 3)
Heart Diseases (Phase 2)
Hemorrhagic Stroke (Phase 3)
HIV Infections (Phase 2/Phase 3)
Ileostomy (Phase 1/Phase 2)
Immunologic Factors (Phase 2)
Infant, Newborn (Phase 3)
Infections (Phase 4)
Inflammatory Bowel Diseases (Phase 2)
Influenza A virus (Phase 3)
Influenza, Human (Phase 3)
Intraabdominal Infections (Phase 4)
Intracranial Hemorrhages (Phase 3)
Ischemic Stroke (Phase 2)
Liver Abscess (Phase 4)
Liver Cirrhosis (Phase 4)
Lyme Disease (Phase 3)
Lyme Neuroborreliosis (Phase 4)
Malnutrition (Phase 2)
Meningitis (Phase 4)
Meniscus (Phase 2)
Neisseria gonorrhoeae (Phase 4)
Neoplasms (Phase 1)
Nephrolithiasis (Phase 4)
Nervous System Diseases (Phase 2)
Osteomyelitis (Phase 4)
Parkinson Disease (Phase 2)
Pelvic Inflammatory Disease (Phase 2)
Peritonitis (Phase 4)
Physiological Effects of Drugs (Phase 2)
Pneumonia (Phase 4)
Pneumonia, Aspiration (Phase 4)
Pneumonia, Bacterial (Phase 3)
Pneumonia, Pneumococcal (Phase 4)
Pneumonia, Ventilator-Associated (Phase 4)
Propranolol (Phase 2)
Prosthesis-Related Infections (Phase 2)
Psychotic Disorders (Phase 1/Phase 2)
Pyelonephritis (Phase 4)
Respiratory Aspiration (Phase 4)
Respiratory Tract Infections (Phase 4)
Schizophrenia (Phase 1/Phase 2)
Sepsis (Phase 4)
Shock, Septic (Phase 4)
Soft Tissue Infections (Phase 2)
Staphylococcal Infections (Phase 4)
Stroke (Phase 3)
Surgical Wound Infection (Phase 4)
Syphilis (Phase 4)
Typhoid Fever (Phase 4)
Urinary Tract Infections (Phase 4)
Urological Manifestations (Early Phase 1)
Ventilators, Mechanical (Phase 4)
Wound Infection (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
